ReviewCurrent pharmacology reports2025
Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals.
Review in Current pharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Antibody-drug conjugate engineering: from design to efficacy and safety.Signal transduction and targeted therapy · 2026Review
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Pharmacokinetic Characterization of the Gastrointestinal Acute Radiation Syndrome Mitigator YK-4-250 in Male and Female Mice Under Non-Irradiated and Partial Body Irradiation Conditions.Research square · 2026Article
- Guiding a Diclofenac Sodium Dual-Release Sustained Formulation Development Through In Vitro-In Vivo Relationship Based on Physiologically Based Pharmacokinetics.Pharmaceutics · 2026Article
- Flavonoid Interactions with Renal Organic Anion Transporters OAT1 and OAT3: Structure-Activity Relationships and Clinical Implications.International journal of molecular sciences · 2026Review
- Flavonoids in Medicine and Food Homology Substances: Structure-Activity Relationship, Application Challenges, and Cutting-Edge Technological Breakthroughs.Foods (Basel, Switzerland) · 2026Review
- Utility of Modeling and Simulations in Drug Development: Contrasting Japan, US and UK Descriptions of PBPK Modeling from Package Inserts.The AAPS journal · 2026Article
- From Population-Based PBPK to Individualized Virtual Twins: Clinical Validation and Applications in Medicine.Journal of clinical medicine · 2026Review
- Optimizing ribociclib dosing in breast cancer with brain metastasis patients using a physiologically based pharmacokinetic model.BMC cancer · 2026Article
- Paeoniflorin as a Promising Therapeutic Candidate in Intestinal Diseases: Experimental Evidence, Mechanistic Insights, and Translational Perspectives.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose of review: Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool to understand drug movements throughout the human body. Unlike classical PK methods that often lack sufficient physiological detail, PBPK integrates drug-specific properties with organism-specific physiological parameters to predict drug behavior in major body compartments, particularly site of action and providing high physiological realism. The aim of the review is to summarize application of PBPK modeling in drug development and in dietary phytochemicals. Recent findings: PBPK modeling is a versatile tool in drug development and phytochemical research. It predicts human PK from preclinical data, aiding lead optimization and candidate evaluation. The model mechanistically predicts drug-drug interactions (DDIs), supporting dose adjustments and reducing clinical trials. PBPK also enables formulation simulation for oral and modified-release drugs, optimizing bioavailability and predicting performance from in vitro data, thus reducing costly in vivo studies. Importantly, it extends drug knowledge to pediatric and special populations via virtual group simulations, enabling efficient, cost-effective dosage determination and less clinical trials. For dietary phytochemicals, PBPK modeling is well-suited for their complex mixture and variability. PBPK studies of phytochemicals demonstrate their utility for single components, mixtures, cross-species extrapolation, and complex metabolic processes, although challenges exist. Summary: PBPK modeling is a dynamic and quantitative tool offering comprehensive pharmacokinetic integration across various populations and regimens. Its importance is growing due to its application at diverse stages of drug development and its ability to adapt to complex substances, including natural products. Ultimately, PBPK modeling is significant for enhancing scientific rigor, expediting drug development and ensuring patient safety. Graphical Abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.